Literature DB >> 27921045

Clinical Scenario of the Metabolic Syndrome.

Swantje Brede1, Georg Serfling1, Johanna Klement1, Sebastian M Schmid1, Hendrik Lehnert1.   

Abstract

The term metabolic syndrome (MeS) refers to a cluster of associated symptoms composed of impaired fasting glucose, abdominal obesity, hypertension, and dyslipidemia. MeS is associated with an increased risk of cardiovascular and diabetes-associated morbidity and mortality. The increased amount of visceral fat together with a chronic inflammatory state predisposes to the development of arteriosclerosis. Furthermore, insulin resistance (IR) and dyslipidemia are associated with fatty liver disease. In addition, MeS is linked to non-cardiovascular diseases such as cancer as well as psychiatric or endocrine disorders. Here, we discuss the clinical impact of MeS in cardiovascular and non-cardiovascular diseases to highlight the importance of prevention, early diagnosis, and multifactorial treatment of high-risk individuals.

Entities:  

Keywords:  Abdominal obesity; Cardiovascular disease; Hyperlipidemia; Insulin resistance; Metabolic syndrome

Year:  2016        PMID: 27921045      PMCID: PMC5123021          DOI: 10.1159/000449028

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  80 in total

Review 1.  Role of adipose tissue in haemostasis, coagulation and fibrinolysis.

Authors:  D R Faber; Ph G de Groot; F L J Visseren
Journal:  Obes Rev       Date:  2009-05-12       Impact factor: 9.213

2.  Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

Authors:  B Lamarche; K D Uffelman; A Carpentier; J S Cohn; G Steiner; P H Barrett; G F Lewis
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

Review 4.  The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome.

Authors:  Renato Pasquali; Valentina Vicennati; Mauro Cacciari; Uberto Pagotto
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

Review 5.  Metabolic syndrome in severe mental disorders.

Authors:  Jude U Ohaeri; Abayomi O Akanji
Journal:  Metab Syndr Relat Disord       Date:  2010-10-21       Impact factor: 1.894

Review 6.  Leptin resistance - or why leptin fails to work in obesity.

Authors:  K El-Haschimi; H Lehnert
Journal:  Exp Clin Endocrinol Diabetes       Date:  2003-02       Impact factor: 2.949

Review 7.  Obesity-induced inflammation: a metabolic dialogue in the language of inflammation.

Authors:  A W Ferrante
Journal:  J Intern Med       Date:  2007-10       Impact factor: 8.989

8.  Adiponectin acts in the brain to decrease body weight.

Authors:  Yong Qi; Nobuhiko Takahashi; Stanley M Hileman; Hiralben R Patel; Anders H Berg; Utpal B Pajvani; Philipp E Scherer; Rexford S Ahima
Journal:  Nat Med       Date:  2004-04-11       Impact factor: 53.440

Review 9.  Abdominal obesity as important component of insulin-resistance syndrome.

Authors:  J P Després
Journal:  Nutrition       Date:  1993 Sep-Oct       Impact factor: 4.008

10.  Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes.

Authors:  Ricardo Fontes-Carvalho; Ricardo Ladeiras-Lopes; Paulo Bettencourt; Adelino Leite-Moreira; Ana Azevedo
Journal:  Cardiovasc Diabetol       Date:  2015-01-13       Impact factor: 9.951

View more
  6 in total

1.  [Nutrition in type 2 diabetes mellitus].

Authors:  S Brede; H Lehnert
Journal:  Internist (Berl)       Date:  2019-01       Impact factor: 0.743

2.  Visceral fat reference values derived from healthy European men and women aged 20-30 years using GE Healthcare dual-energy x-ray absorptiometry.

Authors:  Tomasz Miazgowski; Robert Kucharski; Marta Sołtysiak; Aleksandra Taszarek; Bartosz Miazgowski; Krystyna Widecka
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

3.  Association of circulating calprotectin with lipid profile in axial spondyloarthritis.

Authors:  Fernanda Genre; Javier Rueda-Gotor; Sara Remuzgo-Martínez; Alfonso Corrales; Verónica Mijares; Rosa Expósito; Cristina Mata; Virginia Portilla; Ricardo Blanco; José Luis Hernández; Javier Llorca; Oreste Gualillo; Raquel López-Mejías; Miguel A González-Gay
Journal:  Sci Rep       Date:  2018-09-13       Impact factor: 4.379

Review 4.  The Effect of Time-Restricted Eating on Insulin Levels and Insulin Sensitivity in Patients with Polycystic Ovarian Syndrome: A Systematic Review.

Authors:  R Floyd; R Gryson; D Mockler; J Gibney; S N Duggan; L A Behan
Journal:  Int J Endocrinol       Date:  2022-09-16       Impact factor: 2.803

Review 5.  Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials.

Authors:  Si Qin; Lifan Huang; Jiaojiao Gong; Shasha Shen; Juan Huang; Hong Ren; Huaidong Hu
Journal:  Nutr J       Date:  2017-10-11       Impact factor: 3.271

6.  Evaluation of Monocyte to High-Density Lipoprotein Cholesterol Ratio in the Presence and Severity of Metabolic Syndrome.

Authors:  Ali Ugur Uslu; Yahya Sekin; Gulten Tarhan; Nuray Canakcı; Mehmet Gunduz; Mustafa Karagulle
Journal:  Clin Appl Thromb Hemost       Date:  2017-12-06       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.